SpyGlass Pharma (SGP) director Michael Dybbs files Form 3 with zero ownership

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. director reports no share ownership. Director Michael Dybbs filed an initial insider ownership report stating that he does not beneficially own any non-derivative or derivative securities of SpyGlass Pharma, Inc. This Form 3 establishes his starting ownership position as a board member at zero shares.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dybbs Michael

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/05/2026

3. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Brian Aukshunas, as Attorney-inFact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does SpyGlass Pharma (SGP) director Michael Dybbs report on this Form 3?

He reports that he beneficially owns no securities of SpyGlass Pharma, Inc. This initial Form 3 filing establishes a starting point of zero ownership for his position as a director under insider reporting rules.

Does Michael Dybbs own any SpyGlass Pharma (SGP) shares or options?

According to the filing, he owns no securities of SpyGlass Pharma, Inc. Both the non-derivative and derivative security tables are empty, and the remarks section explicitly states that no securities are beneficially owned.

What insider role does Michael Dybbs hold at SpyGlass Pharma (SGP)?

He is identified as a director of SpyGlass Pharma, Inc. The relationship section of the Form 3 marks the “Director” box, with no officer, 10% owner, or other roles indicated for this reporting person.

Are there any transactions reported in this SpyGlass Pharma (SGP) Form 3?

No transactions are reported in this Form 3. It is an initial ownership report, and the accompanying structured data and tables show no trades or holdings, only that no securities are beneficially owned.

Who signed the Form 3 for SpyGlass Pharma (SGP) director Michael Dybbs?

The form is signed by Brian Aukshunas as attorney-in-fact for the reporting person. The remarks reference an Exhibit 24 Power of Attorney authorizing this individual to sign on behalf of Michael Dybbs.